A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GS-5745 Combined with mFOLFOX6 as First Line Treatment in Patients with Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

Type of Cancer
Gastrointestinal

Site
Sparta

Sponsor
Gilead

Protocol Number
GS-US-296-1080

To Learn More Call
201-510-0910